

# Earnings Review: Barclays PLC ("Barclays")

#### Recommendation

- Barclays' results indicate some fundamental challenges in our view aside from headline numbers that were impacted by one-offs. Underlying earnings benefited from improvement in volatile earnings and cost reductions.
- Although capital ratios were weaker q/q, management are of the view that the business is now positioned for improved performance going forward with legacy conduct issues resolved. As such, results have not altered our Neutral (4) Issuer Profile.
- We are underweight the BACR 3.75 '30c25 due to its long call date. Although the spread at 175bps over swaps is one of the widest in the Tier 2 space, we think there's better value in other European names considering duration and fundamentals such as BNP 4.3% '25c20 and CMZB 4.875% '27c22.

### **Relative Value:**

Bond	Call date	CET1 Ratio	Ask Yield	Spread
BACR 3.75 '30c25	23/05/2025	12.7%	4.29%	175
BNP 4.3 '25c20	03/12/2020	11.9%	3.24%	112
CMZB 4.875 '27c22	01/03/2022	14.1%	4.25%	197

Indicative prices as at 27 April 2018 Source: Bloomberg Common Equity Tier 1 (CET1) Ratio based on latest available quarter

Issuer Profile: Neutral (4)

Ticker: BARC

## **Background**

Based in the UK, **PLC Barclays** ('Barclays') operates in over 50 countries across two main business segments - Barclays UK **Barclays** and International. Its scale in the UK and globally makes Barclays systemically important on both a domestic and global level. As at 31 March 2018, it had total assets of GBP1,142.2bn.

## **Andrew Wong**

+65 6530 4736 WongVKAM@ocbc.com

## Key Considerations

- Results impacted by higher than expected one-off charges: Barclays 1Q2018 results were somewhat mixed with supportive underlying performance overshadowed by large litigation and conduct provisions of GBP2.0bn. These resulted in a loss before tax for the quarter of GBP236mn. Excluding litigation and conduct charges, profit before tax was GBP1.73bn, up 1% y/y. The bulk of the charges comprised a GBP1.4bn settlement with the US Department of Justice ('DoJ') for sales of toxic RMBS from 2005-2007. While this settlement with the DoJ was previously announced, what was unexpected was an additional GBP400mn charge for Payment Protection Insurance ('PPI'). Nevertheless, with total provisions at GBP3.54bn as at 31 December 2017 (and management's assertion that PPI provisions remaining to be used until 29 August 2019 as at 31 March 2018 was GBP1.7bn), recent settlement and higher charges can likely be accommodated within existing resources.
- Solid underlying performance but some challenges remain: Barclays' underlying earnings benefited from improved expense performance with a 45% y/y reduction in credit impairment charges from both single name recoveries and a better US economic outlook as well as a 6% y/y fall in operating expenses. These, along with better performance in Barclays International, offset an 8% fall in total income from weaker performance in the UK, USD depreciation and absence of one-off gains from 1Q2017. In particular, Corporate & Institutional Banking ('CIB') income improved 1% y/y in 1Q2018 as markets related income growth (equities derivatives and financing from increased client activity and market volatility) of 8% mitigated a 4% fall in banking income from lower fee income and an 11% decline in corporate lending. While we caution that improved underlying performance has come from a somewhat volatile income source, the positive trend in expenses provides comfort for future underlying earnings performance.
- Balance sheet growth/risk profile change: Business growth in investment banking (derivatives and securities trading activity) translated into a 2.5% rise in risk weighted assets. This offset the impact on risk weighted assets of USD depreciation against the GBP (-0.6%) and improvements in book quality (-0.3%). Quality improvements largely occurred in Barclays International with the reallocation of RWAs in CIB and repositioning of the US Cards portfolio in Consumer, Cards and Payments. Such movements also explain the weaker



- earnings and lower impairment charges in these respective divisions as part of Barclays' on-going restructuring activities which has in general seen RWAs falling over previous quarters.
- Capital ratios weaker: Barclays' loss before tax for the quarter of GBP236mn contributed to a reduction in Barclays CET1 ratio to 12.7% as at 31 Mar 2018 (13.3% as at 31 Dec 2017). Capital ratios were also impacted by a GBP4.9bn increase in risk weighted assets. These negative movements offset the positive impact on CET1 capital from the implementation of IFRS9. The CET1 ratio is now just below Barclay's expectation for its end state CET1 ratio of around 13%, but nevertheless above its regulatory minimum requirement of around 11.4% (this level is also what management expects would be the Mandatory Distribution Restrictions hurdle). Its UK leverage ratio of 4.8% is also above the transitional minimum requirement of 3.6% as at 31 March 2018 and expected minimum 4.0% requirement applicable from 2019. Management focus on capital will continue to be high in our view, particularly given their intention to return capital to shareholders through dividends and share buybacks in the future.



#### **OCBC Global Treasury**

**Treasury Advisory** 

**Corporate FX & Structured Products** 

Tel: 6349-1888 / 1881 Interest Rate Derivatives

Tel: 6349-1899

**Investments & Structured Products** 

Tel: 6349-1886

**GT Institutional Sales** 

Tel: 6349-1810

Credit Research
Andrew Wong

+65 6530 4736

WongVKAM@ocbc.com

Nick Wong Liang Mian, CFA

+65 6530 7348

NickWong@ocbc.com

Ezien Hoo, CFA

+65 6722 2215

EzienHoo@ocbc.com

**Wong Hong Wei** 

+65 6722 2533

wonghongwei@ocbc.com

## Explanation of Issuer Profile Rating / Issuer Profile Score

**Positive ("Pos") –** The issuer's credit profile is either strong on an absolute basis, or expected to improve to a strong position over the next six months.

**Neutral ("N")** – The issuer's credit profile is fair on an absolute basis, or expected to improve / deteriorate to a fair level over the next six months.

**Negative ("Neg") –** The issuer's credit profile is either weaker or highly geared on an absolute basis, or expected to deteriorate to a weak or highly geared position over the next six months.

To better differentiate relative credit quality of the issuers under our coverage, we have further sub-divided our Issuer Profile Ratings into a 7 point Issuer Profile Score scale.

IPR	Posi	tive	Neutral			Neg <mark>ative</mark>	
IPS	1	2	3	4	5	6	7

#### **Explanation of Bond Recommendation**

**Overweight ("OW")** – The performance of the issuer's specific bond is expected to outperform the issuer's other bonds, or the bonds of other issuers either operating in the same sector or in a different sector but with similar tenor over the next six months.

**Neutral ("N") –** The performance of the issuer's specific bond is expected to perform in line with the issuer's other bonds, or the bonds of other issuers either operating in the same sector or in a different sector but with similar tenor over the next six months.

**Underweight ("UW")** – The performance of the issuer's specific bond is expected to underperform the issuer's other bonds, or the bonds of other issuers either operating in the same sector or in a different sector but with similar tenor over the next six months.

### Other

**Suspension –** We may suspend our issuer rating and bond level recommendation on specific issuers from time to time when OCBC is engaged in other business activities with the issuer. Examples of such activities include acting as a joint lead manager or book runner in a new issue or as an agent in a consent solicitation exercise. We will resume our coverage once these activities are completed.

**Withdrawal ("WD") –** We may withdraw our issuer rating and bond level recommendation on specific issuers from time to time when corporate actions are announced but the outcome of these actions are highly uncertain. We will resume our coverage once there is sufficient clarity in our view on the impact of the proposed action.



#### **Analyst Declaration**

The analyst(s) who wrote this report and/or her or his respective connected persons did not hold securities in the above-mentioned issuer or company as at the time of the publication of this report.

#### Disclaimer for research report

This publication is solely for information purposes only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This publication should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this publication may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This publication may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, they should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. OCBC and/or its related and affiliated corporations may at any time make markets in the securities/instruments mentioned in this publication and together with their respective directors and officers, may have or take positions in the securities/instruments mentioned in this publication and may be engaged in purchasing or selling the same for themselves or their clients, and may also perform or seek to perform broking and other investment or securities-related services for the corporations whose securities are mentioned in this publication as well as other parties generally.

This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).

Co.Reg.no.:193200032W